MaaT Pharma ODYSSEE Study focuses in prevention of dysbiosis complications with autologous fecal microbiota transplantation in Acute Myeloid Leukemia patients undergoing...

Major treatments such as high-dose antibiotic therapies and chemotherapies can lead to serious complications and create a gut microbiota imbalance (formerly called intestinal...

ENTEROME Bioscience SA, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, announces that it has raised €14.5 million in a Series C...

TargEDys, an innovator in appetite regulation, announces a €5.8M “Series A” fundraising round based on world-leading research from company founders Serguei Fetissov and...

Cambrooke Therapeutics, Inc. (“Cambrooke”), a global therapeutic nutrition innovator, is pleased to announce the closing of the Series C investment round, led by Seventure...

MaaT Pharma, a reference for the microbiome industry, is announcing a significant €10 million fundraising operation within the context of its series A. This will notably...

Seventure Partners, one of Europe’s leaders in financing innovation, announces today its investment in MaaT Pharma™, a newly founded French microbiome company. Seventure...

ENTEROME Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, is pleased to announce that...